文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-FAPI-04 PET/CT对消化系统肿瘤患者分期及治疗管理的影响

Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors.
PubMed 文献 · Clin Nucl Med · 2022-11-03

纳入32例消化系统肿瘤患者,均在median 4天内完成指南兼容影像(GCI)与68Ga-FAPI-04 PET/CT并比较分期与治疗决策。68Ga-FAPI-04 PET/CT使15/32例(46.9%)分期改变,8/32例(25.0%)治疗管理受影响。作者认为在肝细胞癌与胰腺导管腺癌中可能支持更广泛采用FAP靶向影像。

要点

  • 68Ga-FAPI-04 PET/CT较GCI使46.9%(15/32)患者分期改变。
  • 分期改变中降期3/15例(20.0%),升期12/15例。
  • 治疗管理受影响8/32例(25.0%),其中主要与次要改变各4例。

核心结论

  • 在消化系统肿瘤患者中,68Ga-FAPI-04 PET/CT使超过46%的病例发生分期改变、25%的病例发生治疗调整,尤其是在肝细胞癌与胰腺导管腺癌患者中。
  • 作者认为在临床常规中,这些发现可能支持在这类肿瘤中更广泛地采用FAP靶向影像。

研究设计与样本

  • 纳入32例消化系统肿瘤患者:结肠腺癌2/32(6.3%)、肝细胞癌6/32(18.8%)、胰腺导管腺癌6/32(18.8%)、胃肠胰神经内分泌肿瘤18/32(56.3%)。
  • 所有患者均在median 4天内完成指南兼容影像(GCI)与68Ga-FAPI-04 PET/CT,并比较两者分期结果与后续治疗决策。

主要发现

  • 与GCI相比,68Ga-FAPI-04 PET/CT使15/32例(46.9%)分期改变。
  • 分期改变者中降期3/15例(20.0%),其余12/15例为升期:肝细胞癌4/12(33.3%)、胰腺导管腺癌4/12(33.3%)、神经内分泌肿瘤3/12(25%)、结肠腺癌1/12(8.3%)。
  • 治疗管理受影响8/32例(25.0%),包括4例主要治疗改变与4例次要治疗改变。
  • 治疗改变比例最高者为胰腺导管腺癌与肝细胞癌患者,为6/8(75%)。

临床怎么用

  • 作者认为在临床常规中,上述发现可能支持在肝细胞癌与胰腺导管腺癌等肿瘤类型中更广泛地采用FAP靶向影像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to determine the impact of fibroblast activation protein inhibitor (FAPI)-directed molecular imaging on staging and therapeutic management in patients affected with digestive system tumors when compared with guideline-compatible imaging (GCI). PATIENTS AND METHODS: Thirty-two patients with tumors of the digestive system were included: colon adenocarcinoma, 2/32 (6.3%); hepatocellular carcinoma (HCC), 6/32 (18.8%); pancreatic duct adenocarcinoma (PDAC), 6/32 (18.8%), and gastroenteropancreatic neuroendocrine neoplasms, 18/32 (56.3%). All patients underwent GCI and 68 Ga-FAPI-04 PET/CT within median 4 days. Staging outcomes and subsequent treatment decisions were compared between GCI and 68 Ga-FAPI-04 PET/CT. RESULTS: Compared with GCI, 68 Ga-FAPI-04 PET/CT led to staging changes in 15/32 patients (46.9%). Among those, downstaging was recorded in 3/15 cases (20.0%) and upstaging in the remaining 12/15 patients (HCC, 4/12 [33.3%]; PDAC, 4/12 [33.3%]; neuroendocrine neoplasms, 3/12 [25%]; colon adenocarcinoma, 1/12 [8.3%]). Therapeutic management was impacted in 8/32 patients (25.0%), including 4 instances of major and 4 instances of minor therapeutic changes. The highest proportion of treatment modifications was observed in patients diagnosed with PDAC and HCC in 6/8 (75%). CONCLUSIONS: In patients affected with digestive system tumors, 68 Ga-FAPI-04 PET/CT resulted in staging changes in more than 46% and therapeutic modifications in 25% of the cases, in particular in patients with HCC and PDAC. In clinical routine, such findings may favor a more widespread adoption of FAP-directed imaging in those tumor types. PURPOSE: We aimed to determine the impact of fibroblast activation protein inhibitor (FAPI)–directed molecular imaging on staging and therapeutic management in patients affected with digestive system tumors when compared with guideline-compatible imaging (GCI). PATIENTS AND METHODS: Thirty-two patients with tumors of the digestive system were included: colon adenocarcinoma, 2/32 (6.3%); hepatocellular carcinoma (HCC), 6/32 (18.8%); pancreatic duct adenocarcinoma (PDAC), 6/32 (18.8%), and gastroenteropancreatic neuroendocrine neoplasms, 18/32 (56.3%). All patients underwent GCI and 68 Ga-FAPI-04 PET/CT within median 4 days. Staging outcomes and subsequent treatment decisions were compared between GCI and 68 Ga-FAPI-04 PET/CT. RESULTS: Compared with GCI, 68 Ga-FAPI-04 PET/CT led to staging changes in 15/32 patients (46.9%). Among those, downstaging was recorded in 3/15 cases (20.0%) and upstaging in the remaining 12/15 patients (HCC, 4/12 [33.3%]; PDAC, 4/12 [33.3%]; neuroendocrine neoplasms, 3/12 [25%]; colon adenocarcinoma, 1/12 [8.3%]). Therapeutic management was impacted in 8/32 patients (25.0%), including 4 instances of major and 4 instances of minor therapeutic changes. The highest proportion of treatment modifications was observed in patients diagnosed with PDAC and HCC in 6/8 (75%). CONCLUSIONS: In patients affected with digestive system tumors, 68 Ga-FAPI-04 PET/CT resulted in staging changes in more than 46% and therapeutic modifications in 25% of the cases, in particular in patients with HCC and PDAC. In clinical routine, such findings may favor a more widespread adoption of FAP-directed imaging in those tumor types. PURPOSE: We aimed to determine the impact of fibroblast activation protein inhibitor (FAPI)–directed molecular imaging on staging and therapeutic management in patients affected with digestive system tumors when compared with guideline-compatible imaging (GCI). PATIENTS AND METHODS: Thirty-two patients with tumors of the digestive system were included: colon adenocarcinoma, 2/32 (6.3%); hepatocellular carcinoma (HCC), 6/32 (18.8%); pancreatic duct adenocarcinoma (PDAC), 6/32 (18.8%), and gastroenteropancreatic neuroendocrine neoplasms, 18/32 (56.3%). All patients underwent GCI and 68Ga-FAPI-04 PET/CT within median 4 days. Staging outcomes and subsequent treatment decisions were compared between GCI and 68Ga-FAPI-04 PET/CT. RESULTS: Compared with GCI, 68Ga-FAPI-04 PET/CT led to staging changes in 15/32 patients (46.9%). Among those, downstaging was recorded in 3/15 cases (20.0%) and upstaging in the remaining 12/15 patients (HCC, 4/12 [33.3%]; PDAC, 4/12 [33.3%]; neuroendocrine neoplasms, 3/12 [25%]; colon adenocarcinoma, 1/12 [8.3%]). Therapeutic management was impacted in 8/32 patients (25.0%), including 4 instances of major and 4 instances of minor therapeutic changes. The highest proportion of treatment modifications was observed in patients diagnosed with PDAC and HCC in 6/8 (75%). CONCLUSIONS: In patients affected with digestive system tumors, 68Ga-FAPI-04 PET/CT resulted in staging changes in more than 46% and therapeutic modifications in 25% of the cases, in particular in patients with HCC and PDAC. In clinical routine, such findings may favor a more widespread adoption of FAP-directed imaging in those tumor types.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kosmala A, Serfling SE, Schlötelburg W, et al. Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors. Clin Nucl Med. 2022. PMID: 36354691. doi:10.1097/RLU.0000000000004480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。